Table 1.
Characteristics of the participants at baseline (modified exposed set).
| Characteristic | RZV group N = 2965 |
Placebo group N = 2991 |
Total N = 5956 |
|---|---|---|---|
| Age (years) at first vaccination | |||
| Mean (±SD) | 62.4 (±7.8) | 62.4 (±7.8) | 62.4 (±7.8) |
| Sex, n (%) | |||
| Male | 1163 (39.2) | 1160 (38.8) | 2323 (39.0) |
| Female | 1802 (60.8) | 1831 (61.2) | 3633 (61.0) |
| Geographic ancestry, n (%) | |||
| Asian/East Asian heritage | 2965 (100) | 2991 (100) | 5956 (100) |
| Age strata, n (%) | |||
| 50–69 years of age | 2330 (78.6) | 2360 (78.9) | 4690 (78.7) |
| ≥ 70 years of age | 635 (21.4) | 631 (21.1) | 1266 (21.3) |
RZV group, participants receiving the adjuvanted recombinant zoster vaccine; placebo group, participants receiving placebo; N, total number of participants; SD, standard deviation; n (%), number (and percentage) of participants in each category.